Perspectives in renal medicine: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia

Kidney International

Volumn 62, Issue 5, 2002, Pages 1524-1538

  Himmelfarb, Jonathan ^a,b,c   Stenvinkel, Peter ^a,b,c   Ikizler, T Alp ^a,b,c   Hakim, Raymond M ^a,b,c  

^a MAINE MEDICAL CENTER   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti oxidative therapy; Blood pressure; Chronic dialysis; End stage renal disease; Hypertension; Mortality and dialysis; Proteinuria

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CYSTEINE; HOMOCYSTEINE; THIOL DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATHETER; CLINICAL TRIAL; CORRELATION ANALYSIS; DIALYSIS; DIALYSIS MEMBRANE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOALBUMINEMIA; INFLAMMATION; KIDNEY TRANSPLANTATION; LIPID PEROXIDATION; MALNUTRITION; MORBIDITY; MORTALITY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UREMIA; METABOLISM; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; HUMANS; OXIDATIVE STRESS; UREMIA;

EID: 0036833743     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00600.x     Document Type: Article

References (99)

1. Foley R, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (Suppl):S112-S119, 1998
2. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356:147-152, 2000
3. Becker BN, Himmelfarb J, Henrich WL, Hakim RM: Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8:475-486, 1997
4. Cheung AK, Sarnak MJ, Yan G, et al: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362, 2000
5. Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989
6. Papa S, Skulachev VP: Reactive oxygen species, mitochondria, apoptosis, and aging. Mol Cell Biochem 174:305-319, 1997
7. Eiserich JP, Hristova M, Cross CE, et al: Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391:393-397, 1998
8. Harrison JE, Schultz J: Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 251:1371-1374, 1976
9. Daugherty A, Dunn JL, Rateri DL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437-444, 1994
10. Heinecke JW: Mass spectrometric quantification of amino acid oxidation products in protein: Insights into pathways that promote LDL oxidation in the human artery wall. FASEB J 13:1113-1120, 1999
11. Hazen SL, Heinecke JW: 3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99:2075-2081, 1997
12. Brown DW, Giles WH, Croft JB: White blood cell count: An independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 54:316-322, 2001
13. Pryor WA: Oxidative stress status: OSS, BOSS, and "Wild Bill" Donovan. Free Radic Biol Med 27:1135-1136, 1999
14. Pryor WA: Forum: Oxidative stress status-The second set. Free Radic Biol Med 28:503-504, 2000
15. Morrow JD, Hill KE, Burk RF, et al: A series of prostaglandin F2-like compounds are produced in vivo by humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87:9383-9387, 1990
16. Handelman GJ, Walter MF, Adhikarla R, et al: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 51:1960-1966, 2001
17. Ikizler TA, Morrow JD, Roberts LJ, et al: Plasma F2 isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol (in press)
18. Salomon RG, Batyreva E, Kaur K, et al: Isolevuglandin-protein adducts in humans: Products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim Biophys Acta 1485:225-235, 2000
19. Sayre LM, Spa W, Xu G, et al: Immunochemical evidence supporting 2-pentylpyrrole formation in proteins exposed to 4-hydroxy-2-nonenal. Chem Res Toxicol 9:1194-1201, 1996
20. Salomon RG, Kaur K, Podrez E, et al: HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques. Chem Res Toxicol 13: 557-564, 2000
21. Ziouzenkova O, Asatryan L, Akmal M, et al: Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. J Biol Chem 274:18916-18924, 1999
22. Heinecke JW, Hsu FF, Crowley JR, et al: Detecting oxidative modification of biomolecules with isotope dilution mass spectrometry: Sensitive and quantitative assays for oxidized amino acids in proteins and tissues. Methods Enzymol 300:124-144, 1999
23. Himmelfarb J, McMenamin E, Loseto G, Heinecke JW: Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 31:1163-1169, 2001
24. Himmelfarb J, McMonagle E, McMenamin E: Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 58:2571-2578, 2000
25. Himmelfarb J, McMonagle E: Manifestations of oxidant stress in uremia. Blood Purif 19:200-205, 2001
26. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, et al: Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. Kidney Int 56:747-753, 1999
27. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524-2532, 1998
28. Witko-Sarsat V, Freidlander M, Capeillere-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996
29. Perna AF, Castaldo P, De Santo NG, et al: Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: Implications for mechanism. Kidney Int 59:2299-2308, 2001
30. Uchida K: Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 28:1685-1696, 2000
31. Miyata T, Van Ypersele De Strihou C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55:389-399, 1999
32. Weiss MF, Erhard P, Kader-Attia FA, et al: Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 57:2571-2585, 2001
33. Miyata T, Ueda Y, Izuhara Y, et al: Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. JAm Soc Nephrol 9:2349-2356, 1998
34. Baynes JW, Monnier VM: The Maillard reaction in aging diabetes and nutrition. Prog Clin Biol Res 304:1-410, 1989
35. Sakata N, Imanaga Y, Meng J, et al: Increased advanced glycation end products in atherosderotic lesions of patients with end-stage renal disease. Atherosclerosis 142:67-77, 1999
36. Berliner JA, Navab M, Fogelman AM, et al: Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91:2488-2496, 1995
37. Uchida K, Itakura K, Kawakishi S, et al: Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys 324:241-248, 1995
38. Schafer FQ, Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Rad Biol Med 30:1191-1212, 2001
39. Deneke SM: Thiol-based antioxidants. Curr Top Cell Regul 36:151-180, 2000
40. Mansoor MA, Svardal AM, Ueland PM: Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma. Annal Biochem 200:218-229, 1992
41. Ueland PM, Mansoor MA, Guttormsen AB, et al: Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status-A possible element of the extracellular antioxidant defense system. J Nutr 126:1281S-1284S, 1996
42. Jones DP, Carlson JL, Mody VC, et al: Redox state of glutathione in human plasma. Free Rad Biol Med 28:625-635, 2000
43. Stamler JS, Slivka A: Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev 54:1-30, 1996
44. Mills BJ, Weiss MM, Lang CA, et al: Blood glutathione and cysteine changes in cardiovascular disease. J Lab Clin Med 135: 396-401, 2000
45. Morrison JA, Jacobsen DW, Sprecher DL, et al: Serum glutathione in adolescent males predicts parental coronary heart disease. Circulation 100:2244-2247, 1999
46. Lapenna D, De Gioia S, Ciofani G, et al: Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 97:1930-1934, 1998
47. Halliwell B, Gutteridge JMC: The antioxidants of human extracellular fluids. Arch Biochem Biophys 280:1-8, 1990
48. Frei B, Stocker R, Ames BN: Small molecule antioxidant defenses in human extracellular fluids, in The Molecular Biology of Free Radical Scavenging, edited by SCANDALIOS J, Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1992, pp 23-45
49. Hu ML, Louie S, Cross CE, et al: Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121:257-262, 1993
50. Soriani M, Pietraforte D, Minetti M: Antioxidant potential of anaerobic human plasma: Role of serum albumin and thiols as scavengers of carbon radicals. Arch Biochem Biophys 312:180-188, 1994
51. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 21:845-853, 1996
52. Hultberg B, Andersson A, Arnadottir M: Reduced, free, and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron 70:62-67, 1995
53. Himmelfarb J, McMenamin E, McMonagle E: Plasma aminothiol oxidation in chronic renal failure. Kidney Int 61:705-716, 2002
54. Stenvinkel P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 10:53-61, 2001
55. Ward RA, McLeish KR: Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. JAm Soc Nephrol 5:1697-1702, 1995
56. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 59:407-414, 2001
57. Nguyen-Khoa T, Massy ZA: Pascal De Bandt J, et al: Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16:335-340, 2001
58. Halliwell B: Commentary: Albumin-An important extracellular antioxidant? Biochem Pharmacol 37:569-571, 1988
59. Himmelfarb J, McMonagle E: Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60:358-363, 2001
60. Miyata T, Ueda Y, Shinzato T, et al: Accumulation of albumin-linked and free-form pentosidine in circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198-1206, 1996
61. Miyata T, Kurokawa K, Van Ypersele de Strihou C: Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 11:1744-1752, 2000
62. Stenvinkel P, Heimburger O, Paultre F, et al: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 51:1899-1911, 1999
63. Foley RN, Parfrey PS, Harnett JD, et al: Hypoalbuminemia, cardiac morbidity and mortality in end-stage renal disease. J Am Soc Nephrol 7:728-736, 1996
64. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
65. 2-isoprostanes and plasma antioxidant potential. Nephrol Dial Transplant 16:1626-1630, 2001
66. Stenvinkel P, Holmberg I, Heimburger O, Diczfalusy U: A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure: Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 13:2594-2600, 1998
67. Vanholder R, Argiles A, Baurmeister U, et al: Uremic toxicity: Present state of the art. Int J Artif Organs 24:695-725, 2001
68. Vanholder R, De Smet R, Vogeleer P, et al: The uraemic syndrome, in Replacement of Renal Function by Dialysis (4th Ed), edited by Jacobs C, Kjellstrand CM, Koch KM, Winchester JF, Boston, Kluwer Academic Publishers, 1996, pp 1-33
69. Himmelfarb J: Urea: Surrogate or toxin? Kidney Int 56:754-755, 1999
70. Horkko S, Savolainen MJ, Kervinen K, Kesaniemi YA: Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int 41:1175-1181, 1992
71. Koch KM: Dialysis-related amyloidosis. Kidney Int 41:1416-1429, 1992
72. 2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition. Clin Nephrol 30:158-163, 1988
73. 2-microglobulin. Biochem Biophys Res Commun 168:1223-1229, 1990
74. Miyata T, Inagi R, Wada Y, et al: Glycation of human beta-microglobulin in patients with hemodialysis-associated amyloidosis: Identification of the glycated sites. Biochemistry 33:12215-12221, 1994
75. 2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J Clin Invest 98:1088-1094, 1996
76. Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 52:10-20, 1997
77. Suliman ME, Anderstam B, Lindholm B, Bergstrom J: Total, free, and protein-bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 12:2332-2338, 1997
78. Nygard O, Nordrehaug JE, Refsum H, et al: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236, 1997
79. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfurcontaining amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262:10098-10103, 1987
80. Roselaar SE, Nazhat JB, Winyard PG, et al: Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48:199-206, 1995
81. Cheung AK: Biocompatibility of dialysis membranes. J Am Soc Nephrol 1:150-161, 1990
82. Parker TF, Wingard RL, Husni L, et al: Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 49:551-556, 1996
83. Tayeb JS, Provenzano R, El-Ghoroury M, et al: Effect of biocompatibility of hemodialysis membranes on serum albumin levels. Am J Kidney Dis 35:606-610, 2000
84. Bloembergen WE, Port FK, Hakim RM, et al: The relationship of dialysis membrane and cause-specific mortality in chronic hemodialysis patients. J Am Soc Nephrol 6:521, 1995
85. Halliwell B: Vitamin C: Antioxidant or pro-oxidant in vivo? Free Rad Res 25:439-454, 1996
86. Lee SH, Oe T, Blair IA: Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science 292:2083-2086, 2001
87. Beuttner GR, Jurkiewicz BA: Catalytic metals, ascorbate and free radicals: Combinations to avoid. Radiat Res 145:532-541,1996
88. Boaz M, Smetana S, Weinstein T, et al: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356:1213-1218, 2000
89. Lonn EM, Yusuf S, Dzavik V, et al: Effects of ramipril and vitamin E on atherosclerosis: A study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103:919-925, 2001
90. Lipid Research Clinics Program: The Lipid Research Clinics coronary primary prevention trial results. JAMA 251:351-374,1984
91. Giardini O, Taccone-Gallucci M, Lubrano R, et al: Effects of alpha-tocopherol administration on red blood cell membrane lipid peroxidation in hemodialysis patients. Clin Nephrol 21:174-177, 1984
92. Ono K: Effects of large dose vitamin E supplementation on anemia in hemodialysis patients. Nephron 40:440-445, 1985
93. Yukawa S, Hibino A, maeda T, et al: Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients. Nephrol Dial Transplant 10:1-3, 1995
94. Lubrano R, Taccone-Gallucci M, Piazza A, et al: Vitamin E supplementation and oxidative status of peripheral blood mononuclear cells and lymphocyte subsets in hemodialysis patients. Nutrition 8:94-97, 1992
95. Lubrano R, Taccone-Gallucci M, Mazzarella V, et al: Relationship between red blood cell lipid peroxidation, plasma hemoglobin, and red blood cell osmotic resistance before and after vitamin E supplementation in hemodialysis patients. Artif Organs 10:245-250, 1986
96. Sanaka T: Takahashi C, Sanaka M, et al: Accumulation of phosphatydilcholine-hydrogen peroxide in dialysis patients with diabetic nephropathy. Clin Nephrol 44:533-537, 1995
97. Cristol JP, Bosc JY, Badiou S, et al: Erythropoiefin and oxidative stress in haemodialysis: Beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 12:2312-2317, 1997
98. Roob JM, Khoschsorur G, Tiran A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549, 2000
99. Islam KN, O'Byrne D, Devaraj S, et al: Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 150:217-224, 2000